Vu Le

Array ( [id] => 18004982 [patent_doc_number] => 20220363748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => ANTI IL-33 THERAPEUTIC AGENT FOR TREATING RENAL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/755604 [patent_app_country] => US [patent_app_date] => 2020-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25692 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17755604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281599 [patent_doc_number] => 20240218073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => IMMUNOMODULATORY ANTI-CD73 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/772092 [patent_app_country] => US [patent_app_date] => 2020-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18034697 [patent_doc_number] => 20220378912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/771353 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18227480 [patent_doc_number] => 20230066474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => LYSOSOME-TARGETING ANTIBODY-DRUG CONJUGATE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/765785 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8868 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20201550 [patent_doc_number] => 12404319 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => Methods and compositions for treating yellow fever [patent_app_type] => utility [patent_app_number] => 17/066299 [patent_app_country] => US [patent_app_date] => 2020-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 2528 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17066299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20272019 [patent_doc_number] => 12441788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Anti-mullerian inhibiting substance antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/763746 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 15824 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945829 [patent_doc_number] => 20220332846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => USE OF ANTI-PCSK9 ANTIBODY IN METHOD FOR PREVENTING OR TREATING CHOLESTEROL-RELATED DISEASE [patent_app_type] => utility [patent_app_number] => 17/642978 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21191 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867078 [patent_doc_number] => 20220289813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => CHIMERIC ANTIGEN RECEPTORS FOR TREATING MYELOID MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/635111 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17635111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533649 [patent_doc_number] => 20220112258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => BIFUNCTIONAL MOLECULES WITH IL-7 ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/278157 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14761 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830113 [patent_doc_number] => 20220267417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => ANTIBODY AGAINST THE OPRF PROTEIN OF PSEUDOMONAS AERUGINOSA, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL COMPOSITION CONTAINING SAME [patent_app_type] => utility [patent_app_number] => 17/629161 [patent_app_country] => US [patent_app_date] => 2020-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 246 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761497 [patent_doc_number] => 20220235109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => NOVEL INTERLEUKIN-2 VARIANTS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/618140 [patent_app_country] => US [patent_app_date] => 2020-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512971 [patent_doc_number] => 20200392229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => METHODS OF USE OF ANTI-SORTILIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/898307 [patent_app_country] => US [patent_app_date] => 2020-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805905 [patent_doc_number] => 20220257740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T CELL RESPONSES [patent_app_type] => utility [patent_app_number] => 17/616941 [patent_app_country] => US [patent_app_date] => 2020-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -146 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776619 [patent_doc_number] => 20220242968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof [patent_app_type] => utility [patent_app_number] => 17/596183 [patent_app_country] => US [patent_app_date] => 2020-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734738 [patent_doc_number] => 20220220197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => Cancer Treatment by Targeting Plexins in the Immune Compartment [patent_app_type] => utility [patent_app_number] => 17/614430 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867113 [patent_doc_number] => 20220289848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => ANTI-CD47/ANTI-PD-L1 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/609532 [patent_app_country] => US [patent_app_date] => 2020-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687769 [patent_doc_number] => 20220195061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS [patent_app_type] => utility [patent_app_number] => 17/609261 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17719128 [patent_doc_number] => 20220211847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => COMBINATION OF MONALIZUMAB, DURVALUMAB, CHEMOTHERAPY AND BEVACIZUMAB OR CETUXIMAB FOR THE TREATMENT OF COLORECTAL CANCER [patent_app_type] => utility [patent_app_number] => 17/609002 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17049 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655434 [patent_doc_number] => 20220175899 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR MUTATED FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR FOR USE IN TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/601282 [patent_app_country] => US [patent_app_date] => 2020-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17601282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790530 [patent_doc_number] => 20220249621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/439926 [patent_app_country] => US [patent_app_date] => 2020-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439926 [rel_patent_id] =>[rel_patent_doc_number] =>)